Apolipoprotein B/A1 and risk of cardiovascular disease. (Q64933119)

1 July 2019

title

Apolipoprotein B/A1 and risk of cardiovascular disease. (English)

1 reference

1 July 2019

1

Lars Lind

1 reference

1 July 2019

language of work or name

English

0 references

publication date

1 July 2008

1 reference

1 July 2019

published in

The Lancet

1 reference

1 July 2019

volume

372

1 reference

1 July 2019

issue

9634

1 reference

1 July 2019

page(s)

185-186

1 reference

1 July 2019

Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961050-8

7 January 2021

Impact of follow-up time and re-measurement of the electrocardiogram and conventional cardiovascular risk factors on their predictive value for myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961050-8

7 January 2021

High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961050-8

7 January 2021

Stroke mortality and the apoB/apoA-I ratio: results of the AMORIS prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961050-8

7 January 2021

Vasodilation in resistance arteries is related to the apolipoprotein B/A1 ratio in the elderly: the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961050-8

7 January 2021

Apolipoprotein B/apolipoprotein A-I in relation to the metabolic syndrome and change in carotid artery intima-media thickness during 3 years in middle-aged men.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961050-8

7 January 2021

Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961050-8

7 January 2021

The apolipoprotein B/AI ratio and the metabolic syndrome independently predict risk for myocardial infarction in middle-aged men.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961050-8

7 January 2021

Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Québec cardiovascular study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961050-8

7 January 2021

Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961050-8

7 January 2021

Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961050-8

7 January 2021

Clinical Utility of Different Lipid Measures for Prediction of Coronary Heart Disease in Men and Women

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961050-8

7 January 2021

10.1016/S0140-6736(08)61050-8

Identifiers

DOI

1 reference

1 July 2019

PubMed ID

18640440

1 reference

1 July 2019